Fundraising Foxmbiomics
3 known investors
Find your way into mbiomics
Sign up to see every warm intro you have to mbiomics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the mbiomics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
mbiomics designs and develops complex Live Biotherapeutic Products (LBPs) based on gut microbiome consortia to treat severe and chronic diseases, with a pipeline spanning oncology (melanoma, NSCLC/renal cell carcinoma), IBD, and ASD. The company combines a data science platform, a proprietary strain library, co-culturing manufacturing, and screening analytics to design and produce indication-specific microbial therapeutics.
Investors · 3
Also in the syndicate · 1
MIG Fonds
Funding
SEC filings, press & company announcementsSource: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does mbiomics do?
- mbiomics designs and develops complex Live Biotherapeutic Products (LBPs) based on gut microbiome consortia to treat severe and chronic diseases, with a pipeline spanning oncology (melanoma, NSCLC/renal cell carcinoma), IBD, and ASD. The company combines a data science platform, a proprietary strain library, co-culturing manufacturing, and screening analytics to design and produce indication-specific microbial therapeutics.
- Who are mbiomics's investors?
- mbiomics's investors include Bayern Kapital, MIG Capital AG.